作者: Anne O. Gang , Michael Pedersen , Francesco d’Amore , Lars M. Pedersen , Bo A. Jensen
DOI: 10.3109/10428194.2015.1010078
关键词:
摘要: The introduction of rituximab and generally improved health among elderly patients have increased the survival with diffuse large B-cell lymphoma (DLBCL). International Prognostic Index (IPI) from 1992 is based on pre-rituximab data clinical trials including several subtypes. We applied IPI factors to a population-based rituximab-treated cohort 1990 diagnosed 2000–2010 explored new optimal prognostic age cut-off for DLBCL. Multivariate-analyses (MVA) confirmed value all except presence > 1 extranodal lesion. was 70 years. In MVA albumin, lymphocyte count, sex, immunoglobulin G, bulky disease, hemoglobin B-symptoms, only albumin prognostic. propose: (1) modified DLBCL index (DLBCL-PI) including: (70 years), performance status (PS), lactate dehydrogenase (LDH), stage level, (2) separate age-adjusted DLBCL-PI ≤ years incl...